To produce high income, increasing at least in line with inflation, from a managed portfolio chiefly invested in UK equities and fixed interest stocks, although with some overseas exposure.
Name | % Net Assets |
---|---|
BP | 8.2% |
BP | 7.7% |
Royal Dutch Shell | 7.7% |
Astrazeneca | 5.9% |
GlaxoSmithKline | 5.0% |
Diageo | 3.7% |
Admiral Group | 3.5% |
ICAP | 3.0% |
Telefónica | 2.9% |
BG | 2.8% |
Key | % Net Assets |
---|---|
BP | 8.2% |
BP | 7.7% |
Royal Dutch Shell | 7.7% |
Astrazeneca | 5.9% |
Other | 70.5% |
Date | 13-Nov-2024 |
---|---|
NAV | 512.48p |
Currency | GBP |
Change | -4.20p |
% | -0.81% |
YTD change | 11.55p |
YTD % | 2.31% |
Fund Inception | 03/08/1987 |
---|---|
Fund Manager | n/a |
TER | 1.83 (31-Oct-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | £100 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.11 |
You are here: research